226 related articles for article (PubMed ID: 29550398)
21. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
22. A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.
Fujita R; Blot V; Wong E; Stewart C; Lieuw V; Richardson R; Banah A; Villicana J; Timmer A; Coronella J; Newman R; Gymnopoulos M
Cancer Biol Ther; 2020 Jun; 21(6):549-559. PubMed ID: 32192391
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract][Full Text] [Related]
24. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
[TBL] [Abstract][Full Text] [Related]
25. HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies.
Gandullo-Sánchez L; Capone E; Ocaña A; Iacobelli S; Sala G; Pandiella A
EMBO Mol Med; 2020 May; 12(5):e11498. PubMed ID: 32329582
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
27. Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin.
Zou L; Ding W; Zhang Y; Cheng S; Li F; Ruan R; Wei P; Qiu B
Biomaterials; 2018 Nov; 182():1-12. PubMed ID: 30096444
[TBL] [Abstract][Full Text] [Related]
28. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker.
Morrison K; Challita-Eid PM; Raitano A; An Z; Yang P; Abad JD; Liu W; Lortie DR; Snyder JT; Capo L; Verlinsky A; Aviña H; Doñate F; Joseph IB; Pereira DS; Morrison K; Stover DR
Mol Cancer Ther; 2016 Jun; 15(6):1301-10. PubMed ID: 26944921
[TBL] [Abstract][Full Text] [Related]
29. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Nishigaki T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hara H; Sugase T; Otsuru T; Saito Y; Tsujii S; Nomura T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Eguchi H; Yamasaki M; Mori M; Doki Y; Naka T
Br J Cancer; 2020 Apr; 122(9):1333-1341. PubMed ID: 32152502
[TBL] [Abstract][Full Text] [Related]
30. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.
Ryan MC; Kostner H; Gordon KA; Duniho S; Sutherland MK; Yu C; Kim KM; Nesterova A; Anderson M; McEarchern JA; Law CL; Smith LM
Br J Cancer; 2010 Aug; 103(5):676-84. PubMed ID: 20664585
[TBL] [Abstract][Full Text] [Related]
31. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.
Greene MK; Chen T; Robinson E; Straubinger NL; Minx C; Chan DKW; Wang J; Burrows JF; Van Schaeybroeck S; Baker JR; Caddick S; Longley DB; Mager DE; Straubinger RM; Chudasama V; Scott CJ
Br J Cancer; 2020 Nov; 123(10):1502-1512. PubMed ID: 32913288
[TBL] [Abstract][Full Text] [Related]
32. Effect of attachment site on stability of cleavable antibody drug conjugates.
Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
[TBL] [Abstract][Full Text] [Related]
33. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97.
Smith LM; Nesterova A; Alley SC; Torgov MY; Carter PJ
Mol Cancer Ther; 2006 Jun; 5(6):1474-82. PubMed ID: 16818506
[TBL] [Abstract][Full Text] [Related]
34. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
35. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
[TBL] [Abstract][Full Text] [Related]
36. Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.
He K; Xu J; Liang J; Jiang J; Tang M; Ye X; Zhang Z; Zhang L; Fu B; Li Y; Bai C; Zhang L; Tao W
Mol Cancer Ther; 2019 Jun; 18(6):1104-1114. PubMed ID: 30962319
[TBL] [Abstract][Full Text] [Related]
37. Novel peptide linkers for highly potent antibody-auristatin conjugate.
Doronina SO; Bovee TD; Meyer DW; Miyamoto JB; Anderson ME; Morris-Tilden CA; Senter PD
Bioconjug Chem; 2008 Oct; 19(10):1960-3. PubMed ID: 18803412
[TBL] [Abstract][Full Text] [Related]
38. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
[TBL] [Abstract][Full Text] [Related]
39. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates.
Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J
Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485
[TBL] [Abstract][Full Text] [Related]
40. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW; Tanlimco SG; Hickson J; Fox M; Sho M; Durkin L; Uziel T; Powers R; Foster K; McGonigal T; Kumar S; Samayoa J; Zhang D; Palma JP; Mishra S; Hollenbaugh D; Gish K; Morgan-Lappe SE; Hsi ED; Chao DT
Cancer Res; 2018 Jul; 78(14):4059-4072. PubMed ID: 29764866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]